Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
32.18-0.36 (-1.11%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close32.54
Bid32.18 x 1600
Ask32.33 x 700
Day's Range32.18 - 32.45
52wk Range28.25 - 37.39
1y Target EstN/A
Market Cap195.19B
P/E Ratio (ttm)28.53
Avg Vol (3m)18,959,096
Dividend & Yield1.20 (3.73%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Investopedia9 minutes ago

    The Biggest Mergers & Acquisitions In The U.S.

    M&A is a daily part of the American business world. They're based on the principle that "One plus one equals three," i.e. they become greater than the sum of their parts.

  • Billionaire Ken Fisher Loves These Dividend Stocks
    Insider Monkey2 days ago

    Billionaire Ken Fisher Loves These Dividend Stocks

    Ken Fisher runs Fisher Asset Management, a hedge fund which manages a portfolio worth over $65.44 billion. Mr. Fisher has authored several books, including 6 best-sellers. He is known to have introduced price-to-sales ratio metric in the investment world. Fisher’s total worth stands at $3.5 billion, according to Forbes’ real-time billionaires’ data. Fisher Asset Management […]

  • PR Newswire2 days ago

    FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

    TOKYO and NEW YORK, Oct. 21, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.